| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Nuclear Medicine |
1 From the Department of Radiology, Division of Nuclear Medicine, Hackensack University Medical Center, 30 Prospect Ave, Hackensack, NJ 07601. Received December 12, 2002; revision requested February 20, 2003; final revision received July 11; accepted August 6. Address correspondence to H.A. (e-mail: hagress@humed.com).
PURPOSE: To determine the clinical importance and malignant potential of unexpected abnormal foci of hypermetabolism at fluorodeoxyglucose (FDG) positron emission tomography (PET) performed for evaluation of malignancy.
MATERIALS AND METHODS: A total of 1,750 FDG PET scans were obtained to evaluate a variety of known or suspected malignancies. Each scan was evaluated for abnormal unexpected hypermetabolism based on unusual location (ie, foci that did not conform to the usual distribution of metastases given the primary tumor for which the PET scan was requested) and discrete focal nature of an abnormality. Unexpected findings were followed by pathologic confirmation and were considered clinically important if the final pathologic diagnosis was cancerous, precancerous, or noncancerous but had the potential for local destruction or systemic physiologic effects.
RESULTS: On the basis of the normal spread pattern of the primary lesion, 58 abnormal unexpected foci of hypermetabolism were identified in 53 patients. Forty-five of these abnormalities were followed up with computed tomography (CT), magnetic resonance imaging, and/or mammography, and 42 had subsequent tissue confirmation at endoscopic, CT-guided, or surgical biopsy. Of 42 histopathologically confirmed abnormalities, 30 (71%) were either malignant or premalignant tumors that differed from the cancer for which the patient was originally scanned. Nine other suspicious abnormal foci proved benign and three represented false-positive findings, with no abnormal findings at endoscopy. Three of nine nonmalignant lesions were considered clinically important because of the potential for local destruction and/or systemic effects.
CONCLUSION: The identification of unexpected foci of hypermetabolism at whole-body FDG PET may signal the presence of tumors that are unrelated to the neoplasm for which the patient was scanned. Findings of this study emphasize the need for follow-up of these abnormalities because the majority represent either malignant or premalignant neoplasms, which were not clinically apparent.
© RSNA, 2003
Index terms: Neoplasms, PET, **.121632 • Positron emission tomography (PET), comparative studies
This article has been cited by other articles:
|
|
 |
|
  Y. Nakamoto, K. Togashi, T. Kaneta, H. Fukuda, K. Nakajima, K. Kitajima, K. Murakami, H. Fujii, M. Satake, U. Tateishi, et al. Clinical Value of Whole-body FDG-PET for Recurrent Gastric Cancer: A Multicenter Study Jpn. J. Clin. Oncol., May 1, 2009; 39(5): 297 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nishizawa, S. Kojima, S. Teramukai, M. Inubushi, H. Kodama, Y. Maeda, H. Okada, B. Zhou, Y. Nagai, and M. Fukushima Prospective Evaluation of Whole-Body Cancer Screening With Multiple Modalities Including [18F]Fluorodeoxyglucose Positron Emission Tomography in a Healthy Population: A Preliminary Report J. Clin. Oncol., April 10, 2009; 27(11): 1767 - 1773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yoshida, S. Borkar, B. Singh, R. A. Ghossein, and H. Schoder Incidental Detection of Concurrent Extramedullary Plasmacytoma and Amyloidoma of the Nasopharynx on [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography J. Clin. Oncol., December 10, 2008; 26(35): 5817 - 5819. [Full Text] [PDF]
|
|
|
|
 |
|
 N K Singh, G J R Cook, V J Lewington, and S C Chua PET/CT assessment of clinically unsuspected, incidental FDG-avid lesions in oncological patients Imaging, September 1, 2008; 20(3): 159 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A Yi, K. M. Shin, K. S. Lee, B.-T. Kim, H. Kim, O J. Kwon, J. Y. Choi, and M. J. Chung Non-Small Cell Lung Cancer Staging: Efficacy Comparison of Integrated PET/CT versus 3.0-T Whole-Body MR Imaging Radiology, August 1, 2008; 248(2): 632 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Milam, M. R. Milam, and R. B. Iyer Detection of Early-Stage Ovarian Cancer by FDG-PET-CT in a Patient With BRCA2-Positive Breast Cancer J. Clin. Oncol., December 10, 2007; 25(35): 5657 - 5658. [Full Text] [PDF]
|
|
|
|
 |
|
 W. De Wever, Y. Vankan, S. Stroobants, and J. Verschakelen Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer Eur. Respir. J., May 1, 2007; 29(5): 995 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Blodgett, C. C. Meltzer, and D. W. Townsend PET/CT: Form and Function Radiology, February 1, 2007; 242(2): 360 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Schoder and M. Gonen Screening for Cancer with PET and PET/CT: Potential and Limitations J. Nucl. Med., January 1, 2007; 48(1_suppl): 4S - 18S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Korn, A. M. Yost, C. C. May, E. R. Kovalsky, K. M. Orth, T. A. Layton, and D. Drumm Unexpected focal hypermetabolic activity in the breast: significance in patients undergoing 18F-FDG PET/CT. Am. J. Roentgenol., July 1, 2006; 187(1): 81 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Schoder, H. W.D. Yeung, and S. M. Larson CT in PET/CT: Essential Features of Interpretation J. Nucl. Med., August 1, 2005; 46(8): 1249 - 1251. [Full Text] [PDF]
|
|
|
|
|
|
H. L. van Westreenen, M. Westerterp, P. L. Jager, H. M. van Dullemen, G. W. Sloof, E. F.I. Comans, J. J. B. van Lanschot, T. Wiggers, and J. Th.M. Plukker Synchronous Primary Neoplasms Detected on 18F-FDG PET in Staging of Patients with Esophageal Cancer J. Nucl. Med., August 1, 2005; 46(8): 1321 - 1325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ishimori, P. V. Patel, and R. L. Wahl Detection of Unexpected Additional Primary Malignancies with PET/CT J. Nucl. Med., May 1, 2005; 46(5): 752 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Israel, N. Yefremov, R. Bar-Shalom, O. Kagana, A. Frenkel, Z. Keidar, and D. Fischer PET/CT Detection of Unexpected Gastrointestinal Foci of 18F-FDG Uptake: Incidence, Localization Patterns, and Clinical Significance J. Nucl. Med., May 1, 2005; 46(5): 758 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Kamel, M. Thumshirn, K. Truninger, M. Schiesser, M. Fried, B. Padberg, D. Schneiter, S. J. Stoeckli, G. K. von Schulthess, and K. D.M. Stumpe Significance of Incidental 18F-FDG Accumulations in the Gastrointestinal Tract in PET/CT: Correlation with Endoscopic and Histopathologic Results J. Nucl. Med., November 1, 2004; 45(11): 1804 - 1810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Pandit-Taskar, H. Schoder, M. Gonen, S. M. Larson, and H. W. D. Yeung Clinical Significance of Unexplained Abnormal Focal FDG Uptake in the Abdomen During Whole-Body PET Am. J. Roentgenol., October 1, 2004; 183(4): 1143 - 1147. [Abstract] [Full Text] [PDF]
|
|
